CáCeres (Nov 07) Final
-
Upload
jescarra -
Category
Health & Medicine
-
view
926 -
download
3
description
Transcript of CáCeres (Nov 07) Final
![Page 1: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/1.jpg)
1
ALS:
Tolerance and survival predictors
ALS:
Tolerance and survival predictors
Cáceres, 10 de Noviembre de 2007
Dr. Joan Escarrabill Hospital Universitari de Bellvitge
L’Hospitalet (Barcelona)[email protected]
![Page 2: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/2.jpg)
2
Agenda
Predictors of tolerance
NIV and survival
Survival and care organization
![Page 3: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/3.jpg)
3
ALS: some figures
Forbes RB et al. J Neurol Neurosurg Psychiatry 2004;75:1753-55
Kimura F et al. Neurology 2006;66:265-7
Mean age at onset
65 yrs
From onset to diagnosis
15 months
Czaplinski A et al. J Neurol 2006;253:1428-36
Diagnostic
Overall median survival 2-4 yrs
Five years survival 11%
Survival > 8 years 4%
Survival
![Page 4: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/4.jpg)
4
Predictors
PEG
Care organization
Bulbar involvement at onset
NIV
Secretions magement
Nihilism
Autonomy
Management of acute problems
Age at onset
![Page 5: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/5.jpg)
5
Limitations of the studies
Long-term studies:– Different diagnostic criteria– Incomplete data
Retrospective studies
Data from patients that “knock to the door”: not population-based studies
The role of PEG and NIV are, in general, underconsidered
No biomarkers
![Page 6: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/6.jpg)
6
Amyotrophic lateral sclerosis
Onset of symptoms
Firstvisit
Onset NIV
Medicaldelay
Unclearfirst symptom
PrecociousNIV
PalliativeEnd-of-life
NIV
Studies are difficult to compare
![Page 7: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/7.jpg)
7
Amyotrophic lateral sclerosis
Onset of symptoms
Firstvisit
Onset NIV
Medicaldelay
Unclearfirst symptom
PalliativeEnd-of-life
NIV
PrecociousNIV
![Page 8: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/8.jpg)
8
Amyotrophic lateral sclerosis
Onset of symptoms
Firstvisit
Onset NIV
Medicaldelay
Unclearfirst symptom
PrecociousNIV
PalliativeEnd-of-life
NIV
![Page 9: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/9.jpg)
9
J Neurol 2006;253:1428-36
Better survival
Younger age
Limb onset
Longer delay before first examination
Higher initial FVC = Longer survival
Lower initial AALS score
Includes assessment of swallowing, speech, and respiratory function, and both strength and function of upper and lower extremity musculature
Appel V. Ann Neurol. 1987;22:328-33.
![Page 10: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/10.jpg)
10
Neurology 2005;64:38-43
Symptom duration at baseline visit was a significant predictor of survival
Shorter duration = Higher mortality
Symptom duration at first visit related to rate of disease progression
ALSFRS-R Physical function in daily living activities
Salivation Swallowing4
3
21
0
4
3
21
0
Cedarbaum JM. J Neurol Sci 1999;169:13-21
![Page 11: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/11.jpg)
11
J Neurol Neurosurg Psychiatry 2004;75:1753-55
Scottish ALS Register
n=1226
Medical nihilism ?
Riluzole & PEG use increases
Patient autonomy
Less aggressive therapy
2.4 months
![Page 12: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/12.jpg)
12
ALS: Acute chest infection
Servera E. J Neurol Sci 2003;209:111-3
65 yrs old man
Daytime Mouth pieceNasal mask for nocturnal use
![Page 13: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/13.jpg)
13
Secretions management
MI-E
Ventilador+30 +TAT
Ventilador+TAT
Air stacking+TAT
TATSPON + m
ot
SPON
1100
1000
900
800
700
600
500
400
300
200
100
0
٭
٭
٭
٭
٭
†
††
†
‡
‡‡
• P
CF
l/m
n
Courtesy of Cristina Senent MD (H. Sant Joan - Alacant)& Jesus González MD (Hôpital Pitié-Salpetière - Paris)
![Page 14: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/14.jpg)
14
Bulbar impairment
BulbarNon-Bulbar
Bourke SC. Lancet Neurol 2006;5:140-7
![Page 15: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/15.jpg)
15
Survival in ALS patients with bulbar involvement
Farrero et al. Chest 2007;127:2132-8
NIV Tolerance
NIV intolerance
NIV Tolerance
NIV intolerance
Hypercapnia
Normocapnia
NIV Tolerance
NIV intolerance
![Page 16: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/16.jpg)
16
Agenda
Predictors of tolerance
NIV and survival
Survival and care organization
![Page 17: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/17.jpg)
17
Survival on HMVLaub M & Midgren B. Respir Med 2007;101:1074-8
n=1526
ALS
![Page 18: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/18.jpg)
18
Indication of NIV
Melo J. J Neurol Sci 1999;169:114-7
n=2357 patients
15% on NIV
![Page 19: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/19.jpg)
19
Lancet Neurol 2006;5:140-7
![Page 20: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/20.jpg)
20
Lancet Neurol 2006;5:140-7
![Page 21: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/21.jpg)
21
Lancet Neurol 2006;5:140-7
Time SAQLI symptoms domain maintained above 75% of prerandomization assessment
BulbarNon-Bulbar
![Page 22: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/22.jpg)
22
Are NIV trials necessaries in ALS with non-bulbar impairement?
Servera E. Sancho S. Lancet Neurol 2006;5:140-7
Ethical issues
Non-bulbar patients in control group
Stop studies according the results
Technical issues
Assessment effects of NIV
Pressure vs volume ventilators
Secretion management
It’s mandatory to evaluate therapy “package”
![Page 23: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/23.jpg)
23
Chest 2007;132:62-9
Median survival time 37 months
Lenght of hospital stay55 days (7-124)
91% home discharge
![Page 24: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/24.jpg)
24
Agenda
Predictors of tolerance
NIV and survival
Survival and care organization
![Page 25: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/25.jpg)
25
Zoccolella S et al. J Neurol 2007;254:1107-12
No improvements in survival: Low rate of interventions?
![Page 26: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/26.jpg)
26
Survival of Irish ALS patients
One year mortality wasdecreased by 29.7%
![Page 27: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/27.jpg)
27
Survival of Irish ALS patients with bulbar onset
Prognosis of bulbar onset patients was extended by 9.6 months
![Page 28: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/28.jpg)
28
ALS patients who received their care at a multidisciplinary clinic had a better prognosis
Recruitment bias
ALS clinic treated a group of fitter ALS patients
General neurologistssaw all ALS patients
Living further from ALS clinicMore disabledIncreased ageBulbar onsetShorter duration of illness
Hutchinson M. J Neurol Neurosurg Psychiatry 2004;75:1208-12
![Page 29: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/29.jpg)
29
J Neurol Neurosurg Psychiatry 2006;77:948-50
Tertiary center
Neurology clinic
1080 days
775 days
The median survival from onsetwas 10 months longer
in ALS centers
4 yrs youngerPEG & NIV more oftenLess hospital admissions
![Page 30: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/30.jpg)
30
Chest 2007;127:2132-8
Early systematic respiratory evaluation is necessary to improve the results
Of HMV in ALS
Survival in patients without bulbar involvement
Protocol
Pre-Protocol
![Page 31: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/31.jpg)
31
www.has-sante.fr/
2003 17 Reference centers
CoodinationWorking groupsLocal organization
![Page 32: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/32.jpg)
32
Local organization
Visite de “retourn d’annonce”
Care planningSocial supportCall center
2-3 weeks after diagnostic
Hôpital Pitié SalpetièreParis
Multidisciplinary teamDay hospitalRespiratory unit
Median survival on HMV: 18 months
J. González-Bermejo, MD
![Page 33: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/33.jpg)
33
Escarrabill J. Arch Bronconeumol 2007;43:527-9
Patient-centered care: accessibility vs performance
Reference centers: benefits and limits
Improve skills & knowledge
DistanceUnnecessary referals
+
-
![Page 34: CáCeres (Nov 07) Final](https://reader034.fdocuments.net/reader034/viewer/2022052601/558ba551d8b42a146d8b461d/html5/thumbnails/34.jpg)
34
Conclusions
Nihilism is bad
It seems that patients don’t like agressive treatments
Integrated care is a good option